Effect and Mechanism of QiShenYiQi Pill on Experimental Autoimmune Myocarditis Rats

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2016 Mar 7

PMID 26946470

Citations 8

Authors

Shichao Lv

Meifang Wu

Meng Li

Qiang Wang

Ling Xu

Xiaojing Wang

Junping Zhang

Affiliations

Soon will be listed here.

Abstract

Background: To observe the effect of QiShenYiQi pill (QSYQ) on experimental autoimmune myocarditis rats, and to explore its mechanism of action.

Material/methods: Lewis rats underwent the injection of myocardial myosin mixed with Freund's complete adjuvant were randomized into 3 groups: model, valsartan, and QSYQ groups. Rats injected with phosphate-buffered saline (PBS) mixed with Freund's complete adjuvant were used as the control group. Rats were euthanized at 4 and 8 weeks, and we weighed rat body mass, heart mass, and left ventricular mass. Myocardium sections were stained with hematoxylin and eosin (H&E) and Masson trichrome. Myocardial TGF-β1 and CTGF protein expression was detected by immunohistochemistry, and myocardial TGF-β1 and CTGF mRNA expression was detected by real-time qPCR.

Results: QSYQ reduced HMI and LVMI, as well as the histological score of hearts and CVF, which further decreased over time, and its effect was significantly greater than that of valsartan at 4 and 8 weeks. After 4 weeks, QSYQ inhibited the protein and mRNA expression of TGF-β1 and CTGF, and its effect on lowering CTGF was significantly greater than that of valsartan. In addition, after 8 weeks, QSYQ also inhibited the protein and mRNA expression of CTGF, whereas there was no significant difference in the expression of myocardial TGF-β1.

Conclusions: This study provides evidence that QSYQ can improve cardiac remodeling of experimental autoimmune myocarditis rats. It also effectively improved the degree of myocardial fibrosis, which is related to the mechanism of regulation of TGF-β1 CTGF.

Citing Articles

Syndecan-4 is More Sensitive in Detecting Hypertensive Left Ventricular Diastolic Dysfunction in 2K2C Rats.

Dai W, Liu Y, Yao F, Li W, Liu J, Li C Int J Hypertens. 2022; 2022:1447425.

PMID: 36248198 PMC: 9553681. DOI: 10.1155/2022/1447425.

QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy.

Lv S, Zhang W, Yuan P, Lu C, Dong J, Zhang J Pharm Biol. 2022; 60(1):722-728.

PMID: 35361037 PMC: 8979511. DOI: 10.1080/13880209.2022.2056206.

Cellular and Molecular Mechanism of Traditional Chinese Medicine on Ventricular Remodeling.

Zhu Y, Liang B, Gu N Front Cardiovasc Med. 2021; 8:753095.

PMID: 34926607 PMC: 8671630. DOI: 10.3389/fcvm.2021.753095.

QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats.

Lv S, Wang Q, Wu M, Li M, Wang X, Xu L Evid Based Complement Alternat Med. 2021; 2021:5536723.

PMID: 34221074 PMC: 8225423. DOI: 10.1155/2021/5536723.

QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy.

Lv S, Yuan P, Dong J, Lu C, Li M, Qu F J Cell Mol Med. 2020; 24(19):11283-11293.

PMID: 32881330 PMC: 7576289. DOI: 10.1111/jcmm.15695.

References

Fairweather D, Frisancho-Kiss S, Yusung S, Barrett M, Davis S, Gatewood S . Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol. 2004; 165(6):1883-94. PMC: 1618717. DOI: 10.1016/s0002-9440(10)63241-5. View

Au C, Butler T, Sherwood M, Egan J, North K, Winlaw D . Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol. 2010; 92(1):57-65. PMC: 3052757. DOI: 10.1111/j.1365-2613.2010.00750.x. View

Lang C, Sauter M, Szalay G, Racchi G, Grassi G, Rainaldi G . Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med (Berl). 2007; 86(1):49-60. DOI: 10.1007/s00109-007-0249-3. View

Chen M, Lam A, Abraham J, Schreiner G, Joly A . CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 2000; 32(10):1805-19. DOI: 10.1006/jmcc.2000.1215. View

Weber K . Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989; 13(7):1637-52. DOI: 10.1016/0735-1097(89)90360-4. View

Yun S, Shin J, Lim B, Kim K, Gil C, Kim D . Change in the cells that express connective tissue growth factor in acute Coxsackievirus-induced myocardial fibrosis in mouse. Virus Res. 2007; 126(1-2):62-8. DOI: 10.1016/j.virusres.2007.01.016. View

Yunfei L, Haibin Q, Yiyu C . Identification of major constituents in the traditional Chinese medicine "QI-SHEN-YI-QI" dropping pill by high-performance liquid chromatography coupled with diode array detection-electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2008; 47(2):407-12. DOI: 10.1016/j.jpba.2007.12.037. View

Chen P, Xie Y, Shen E, Li G, Yu Y, Zhang C . Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol. 2011; 658(2-3):168-74. DOI: 10.1016/j.ejphar.2011.02.040. View

Lv S, Rong J, Ren S, Wu M, Li M, Zhu Y . Epidemiology and diagnosis of viral myocarditis. Hellenic J Cardiol. 2013; 54(5):382-91. View

10.

Lei B, Hitomi H, Mori T, Nagai Y, Deguchi K, Mori H . Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts. J Pharmacol Sci. 2011; 117(2):98-105. PMC: 3230079. DOI: 10.1254/jphs.11065fp. View

11.

Tang D, Zhao H, Pan C, Liu Y, Wei X, Yang X . QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats. Evid Based Complement Alternat Med. 2013; 2013:480597. PMC: 3600323. DOI: 10.1155/2013/480597. View

12.

Chen H, Fan W, Jin X, Wang Q, Zhou J, Shi Z . [Changing trends of etiologic characteristics of cardiovascular diseases among inpatients in Shanghai: a retrospective observational study from 1948 to 1999]. Zhonghua Nei Ke Za Zhi. 2004; 42(12):829-32. View

13.

Shiono T, Kodama M, Hanawa H, Fuse K, Yamamoto T, Aizawa Y . Suppression of myocardial inflammation using suramin, a growth factor blocker. Circ J. 2002; 66(4):385-9. DOI: 10.1253/circj.66.385. View

14.

Matsumoto Y, Tsukada Y, Miyakoshi A, Sakuma H, Kohyama K . C protein-induced myocarditis and subsequent dilated cardiomyopathy: rescue from death and prevention of dilated cardiomyopathy by chemokine receptor DNA therapy. J Immunol. 2004; 173(5):3535-41. DOI: 10.4049/jimmunol.173.5.3535. View

15.

Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A . A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990; 57(2):250-62. DOI: 10.1016/0090-1229(90)90039-s. View

16.

Zhang Y, Shi P, Yao H, Shao Q, Fan X . Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen yiqi pills) in rats. Curr Drug Metab. 2012; 13(5):510-23. DOI: 10.2174/1389200211209050510. View

17.

Liu P, Mason J . Advances in the understanding of myocarditis. Circulation. 2001; 104(9):1076-82. DOI: 10.1161/hc3401.095198. View

18.

Santibanez J, Quintanilla M, Bernabeu C . TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011; 121(6):233-51. DOI: 10.1042/CS20110086. View

19.

Palaniyandi Selvaraj S, Watanabe K, Ma M, Tachikawa H, Kodama M, Aizawa Y . Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull. 2005; 28(11):2128-32. DOI: 10.1248/bpb.28.2128. View

20.

Dean R, Balding L, Candido R, Burns W, Cao Z, Twigg S . Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem. 2005; 53(10):1245-56. DOI: 10.1369/jhc.4A6560.2005. View